Can this protocol be signed electronically?

Yes. Electronic signatures are legally valid under the federal ESIGN Act (15 U.S.C. ch. 96) and UETA in states that adopted it, provided intent, consent, attribution, and retention requirements are met.

Are e-records acceptable for FDA submissions?

FDA-regulated electronic records and signatures must meet 21 CFR Part 11 controls when required. Ensure technical controls for audit trails, access controls, and record integrity are documented.

Do I need a notary or witness for protocol signatures?

Most protocols do not require notarization; if a state or sponsor requires notarization or witnesses, follow state rules. For remote notarization, confirm state RON acceptance and ID-proofing requirements.

How do I keep PHI compliant when eSigning?

Use a vendor that will sign a Business Associate Agreement, limit access controls, and retain encrypted audit logs. Document HIPAA safeguards in your protocol and vendor agreements.

What retention rules apply to protocol records?

Follow federal baselines: retain tax and financial records at least 3 years (IRC §6501(a)) and HIPAA-related records 6 years (45 CFR §164.530(j)); longer retention may be required by sponsor or state law.

Who can sign on behalf of a sponsor or site?

Only individuals authorized by organizational policy or delegation logs should sign. Document signer authority and retain delegation records to support attribution and regulatory inspection.

Electronic Signature
Templates
Healthcare
Healthcare FDA Protocol

Healthcare FDA Protocol

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

HEALTHCARE FDA PROTOCOL

Protocol Identification

Protocol Title:

Protocol ID: Sponsor:

Sponsor Contact Study Site / Institution Principal Investigator

Study Overview

Clinical Phase: Indication:

Study Population:

Estimated Number of Subjects:

Objectives

Primary Objective Secondary Objectives

Background and Rationale

Study Design and Procedures

Design Overview

Randomization: Blinding:

Study Duration and Visit Schedule

Eligibility Criteria

Inclusion Criteria Exclusion Criteria

Investigational Product / Device

Description Dosing / Use Schedule Concomitant Medication Restrictions

Safety Monitoring and Reporting

Safety Monitoring Plan: Investigator will monitor subject safety in accordance with applicable regulations and sponsor requirements. Serious adverse events must be reported as specified below.

Safety Contact (24/7)

Serious Adverse Event Reporting: Investigator must notify Sponsor and IRB immediately and file required reports within the timelines mandated by regulation.

SAE Report Timeline:

Regulatory, Ethics and Data Management

The study will be conducted in accordance with applicable federal regulations, Good Clinical Practice, and the protocol. The Investigator shall maintain accurate source documents and retain records for the period required by applicable regulation.

IRB Approval Date IRB Expiration Date Data Custodian Data Storage Location

HIPAA and Privacy: Investigator and Sponsor will maintain subject confidentiality. Required authorizations will be obtained prior to the collection or use of protected health information. Acknowledged

Protocol Amendments and Deviations

All amendments to this protocol must be submitted for IRB review and Sponsor approval prior to implementation, except where immediate change is necessary to protect subject safety. Deviations must be documented and reported according to Sponsor policy and regulatory requirements.

Participant Screening Record (for initial enrollment)

Patient Full Name Date of Birth Gender Address

Phone

Emergency Contact

Insurance and Medical History

Insurance Provider

Policy Number

Group Number

Subscriber Name Current Medications Allergies Prior Surgeries / Hospitalizations Chronic Medical Conditions

Certifications and Signatures

The Sponsor certifies that this protocol contains accurate procedural descriptions and that all investigational supplies will be handled in accordance with applicable regulatory requirements. The Principal Investigator certifies that he/she will conduct the study in accordance with the protocol, applicable regulations, and will obtain informed consent from each subject prior to any study procedure.

Sponsor:

By:

Date:

Principal Investigator:

By:

Date:

What the Healthcare FDA Protocol Is and when it matters

A Healthcare FDA Protocol is a formal, written plan that documents the objectives, design, conduct, data handling, and safety monitoring for a clinical investigation or regulated healthcare study submitted to FDA or used to meet FDA expectations. It defines study endpoints, subject eligibility, adverse event reporting procedures, data integrity controls, and versioning rules. For electronic records and signatures the protocol should align with 21 CFR Part 11 controls and be structured so audit trails, document histories, and reproducible copies are available for inspection and regulatory review.

Why a clear Healthcare FDA Protocol matters

A well-prepared protocol reduces regulatory risk, clarifies responsibilities for investigators and sponsors, supports consistent data collection, and streamlines FDA review. It documents safety reporting timelines and data controls that are necessary for compliance with FDA expectations and for maintaining audit-ready electronic records.

Typical roles that prepare or sign the protocol

The Healthcare FDA Protocol is completed and reviewed by cross-functional teams responsible for study conduct and regulatory compliance.

Principal Investigator — Leads study conduct, confirms clinical sections and safety monitoring responsibilities for sites.
Regulatory Affairs / RA Specialist — Ensures protocol language meets FDA expectations and coordinates submissions and correspondence.
Sponsor / CRO Representative — Owns version control, document distribution, and certifies resources for monitoring and data management.

Final signers typically include authorized clinical leads and corporate signatories who accept responsibility for protocol content and compliance.

Core sections to include in a professional protocol

A robust Healthcare FDA Protocol contains standard sections so reviewers and inspectors can verify scientific rationale, safety oversight, and data integrity controls quickly.

Study Objectives

Clearly state primary and secondary objectives, hypotheses, and measurable endpoints so reviewers evaluate study purpose and statistical analysis plans.

Eligibility Criteria

Define inclusion/exclusion criteria, enrollment caps, and screening procedures to ensure consistent subject selection across sites and reproducible populations.

Endpoints & Assessments

Describe primary/secondary endpoints, assessment timing, validated measurement instruments, and handling of missing data for statistical integrity.

Safety Monitoring

Specify adverse event definitions, reporting timelines, Data Monitoring Committee duties, and expedited reporting procedures required under 21 CFR Part 312 or applicable guidance.

Data Management

Document source data definitions, electronic data capture controls, audit trails, backup procedures, and 21 CFR Part 11 technical controls for e-records.

Version Control

Provide amendment procedures, effective dates, distribution lists, and a master revision history to track approvals and ensure sites use the current protocol.

Step-by-step: preparing and finalizing the protocol

Follow these sequential steps to prepare, approve, sign, and distribute a regulated Healthcare FDA Protocol.

01

Draft Protocol: Assemble clinical, statistical, and safety sections for internal review.
02

Internal Review: Solicit RA, QA, legal, and clinical feedback and resolve comments.
03

Signatures: Collect authorized electronic signatures with required authentication.
04

Distribute & Archive: Issue the approved version to sites, update tracking, and archive prior drafts.

How to configure an online workflow for this protocol

Map document fields, signer roles, and authentication settings before sending to ensure correct routing and audit trails.

Field	Configuration
Document Template	Use a locked template with variable fields for site-specific data.
Conditional Sections	Show or hide sections based on study phase or device arm.
Signer Roles	Assign PI, sponsor, and QA reviewers in signing order.
Authentication	Enable email, SMS code, or stronger MFA per risk level.

Where to send and how submissions flow

A typical eSubmission workflow routes the signed protocol to internal archives, IRBs, and the appropriate FDA e-submission channel or sponsor repository.

Prepare Document: Finalize PDF/A or eCTD-ready files for submission.
Assign Signers: Add signers and set signing order and authentication.
Collect eSignatures: Capture electronic signatures and automatic audit trail.
Archive & Submit: Distribute copies to IRB, sponsor archive, and FDA portal.

Technical and integration considerations

Confirm that the chosen platform captures tamper-evident audit trails, stores records with AES-256 encryption, and can export reproducible copies for inspection.

Integrations: Salesforce, NetSuite, Microsoft 365, Google Workspace
File Formats: PDF, PDF/A, DOCX, XML for eCTD assemblies
Authentication: SMS code, SSO, or advanced signer verification

Key timelines and regulatory deadlines to track

Track internal and regulatory deadlines to ensure timely IRB approvals, site activations, and expedited safety reporting under FDA rules.

IRB Review Window:

Expect 30–60 days for full board review depending on IRB schedule.

Site Activation:

Allow 2–8 weeks for contracting, training, and site initiation.

IND Safety Reports:

Fatal or life‑threatening events reported within 7 days (21 CFR 312.32).

Other AE Reporting:

Serious, unexpected events reported within 15 days (21 CFR 312.32).

Version Effective Date:

Use protocol effective date to control site usage and tracking.

Sequential milestones from draft to submission

Track major milestones to maintain an audit-ready trail and ensure each approval precedes the next step.

01

Protocol Drafting

Complete initial draft with clinical and statistical sections.

02

Internal Approval

Obtain sponsor and QA sign-off before external review.

03

IRB Approval

Secure IRB approval or exemption for each participating site.

04

Regulatory Submission

Submit signed protocol and supporting docs to FDA or repository.

Security and compliance items to document

Encryption: TLS 1.2/1.3 in transit; AES-256 at rest

Audit Trail: Tamper-evident logs with timestamps

HIPAA: BAA required for protected health data

21 CFR Part 11: Controls for electronic records and signatures

SOC 2: SOC 2 Type II compliance available

Accessibility: WCAG 2.0 Level AA conformance

Consequences of incorrect or incomplete protocols

Regulatory Warning: May trigger FDA warning letter

Inspection Risk: Increased likelihood of inspection findings

Data Rejection: Possible rejection of study data by FDA

Study Delays: Delays in approvals or site activation

Financial Exposure: Increased costs for remediation

Legal Liability: Potential civil or contractual claims

Common mistakes when preparing a Healthcare FDA Protocol

Failing to align electronic record controls with 21 CFR Part 11, which can leave audit trails incomplete or signatures inadequately authenticated.
Using inconsistent protocol titles, numbers, or dates across submission materials, creating confusion during regulatory or IRB review.
Omitting clear safety reporting triggers or timelines, which risks late reporting and regulatory noncompliance under FDA safety rules.
Not validating signer authority or role delegation, resulting in signatures that cannot be attributed to an authorized representative.

Real-world examples of protocol use and execution

These concise case narratives describe how organizations applied electronic protocols and eSigning in regulated workflows.

Fertility Centers of Illinois

The center standardized protocol versions across clinics to reduce variability and support audits.

Protocol version control enforced at signing.
The approach reduced review cycles and ensured consistent site compliance during inspections, improving document traceability across clinical locations.

Martin Properties (onsite health screening)

A property management firm used electronic protocols for contractor health checks to speed site onboarding.

Mobile signing reduced turnaround time.
Electronic distribution and audit trails supported faster contractor clearance while maintaining a reproducible record for compliance and insurance.

eSignature vendor comparison for regulated protocol workflows

Selected vendors and common feature criteria to consider for HIPAA, audit trail, bulk send, and pricing. signNow is listed first for comparison consistency.

	signNow	DocuSign	Adobe Sign	PandaDoc	HelloSign
Starting Price	$8/user/mo	$15/user/mo	$14/user/mo	$19/user/mo	$15/user/mo
Free Trial	7-day free trial	No	No	Yes, limited	Yes, limited
Bulk Send	Yes	Yes	Yes	Yes	No
Audit Trail	Yes	Yes	Yes	Yes	Yes
HIPAA Compliant	Yes	Yes	Yes	No	No

Frequently asked questions about Healthcare FDA Protocols and eSigning

Answers to common legal, technical, and process questions encountered when preparing and executing regulated protocols.

Need help? Contact support

Can this protocol be signed electronically?
Yes. Electronic signatures are legally valid under the federal ESIGN Act (15 U.S.C. ch. 96) and UETA in states that adopted it, provided intent, consent, attribution, and retention requirements are met.
Are e-records acceptable for FDA submissions?
FDA-regulated electronic records and signatures must meet 21 CFR Part 11 controls when required. Ensure technical controls for audit trails, access controls, and record integrity are documented.
Do I need a notary or witness for protocol signatures?
Most protocols do not require notarization; if a state or sponsor requires notarization or witnesses, follow state rules. For remote notarization, confirm state RON acceptance and ID-proofing requirements.
How do I keep PHI compliant when eSigning?
Use a vendor that will sign a Business Associate Agreement, limit access controls, and retain encrypted audit logs. Document HIPAA safeguards in your protocol and vendor agreements.
What retention rules apply to protocol records?
Follow federal baselines: retain tax and financial records at least 3 years (IRC §6501(a)) and HIPAA-related records 6 years (45 CFR §164.530(j)); longer retention may be required by sponsor or state law.
Who can sign on behalf of a sponsor or site?
Only individuals authorized by organizational policy or delegation logs should sign. Document signer authority and retain delegation records to support attribution and regulatory inspection.

be ready to get more

Join over 28 million airSlate SignNow users

Sign Now